Loading…
← CockpitCompetitor Analysis › BLISSGVS.NS Bliss GVS Pharma LimitedOpen in the cockpit ↗

Bliss GVS Pharma LimitedBLISSGVS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 99
Mkt cap
$777M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$1.31M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.5 pp
WACC 12.5%
Hurdle
+24 pp
Req g minus delivered
Close · INR₹680.35
1D+3.7%
1W+3.7%
1M+8.5%
3M+24.5%
6M+140.6%
YTD+316.4%
1Y+323.4%
ATR %5.0%
Beta0.89
52w lowhigh8.1% off high

What Bliss GVS Pharma does

Employees: 1,033

Bliss GVS Pharma at a glance

Size Bliss GVS Pharma (BLISSGVS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $777M, the 689th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹680.35 on 18 Nov 2026.

Performance Over six months the shares gained 140.6%, against -7.0% for the median peer and +3.8% for the India market (cap-weighted) — highest of 19 in its peer set.

Growth Revenue grew 24.9% over the last twelve months (peer median +5.2%); the operating margin is 18.5% (peer median 8.9%).

Valuation It trades at 6.7× enterprise value to sales against a peer median of 2.5× (4th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points below its cost of capital (12.5% WACC).

Relative performance

10015020025021 May 202621 Aug 202618 Nov 2026BLISSGVS.NS 235Peer median 94
Six months, rebased to 100: Bliss GVS Pharma against the median of its 20 peers (local-currency closes).

Bliss GVS Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹10.7B₹9.21B₹8.02B₹7.66B₹7.47B
Revenue growth—+15%+5%+2%—
Gross profit₹4.28B₹3.07B₹2.33B₹2.49B₹2.33B
EBITDA₹2.36B₹1.66B₹1.23B₹1.49B₹1.17B
Net income₹1.61B₹1.29B₹843M₹755M₹709M
Free cash flown/a₹839M₹392M₹734M-₹525M
Capital expendituren/a₹568M₹763M₹283M₹938M
Total debt₹226M₹218M₹881M₹998M₹1.02B

Quarterly statements and history in the cockpit →

Bliss GVS Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%000411002390ARDX002349LXRX3001IRWDGUDORICSANOFI002424RIGL688073SUVEN0029072171BLISSGVS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Bliss GVS Pharma is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×250×500×750×000411002390ARDX002349LXRXIRWDGUD002424SUVEN2171BLISSGVS.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bliss GVS Pharma is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%0023900023493001GUDSANOFI002424RIGL688073002907COLL600479BLISSGVS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bliss GVS Pharma is the large dot.

Bliss GVS Pharma competitors and peer comparison

How Bliss GVS Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bliss GVS Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureBLISSGVS.NSPeer medianRank in peer set
1-month return+8.5%-3.8%6th highest of 19
6-month return+140.6%-7.0%highest of 19
Distance from 52-week high-8.1%-33.9%2nd highest of 19
Revenue growth (TTM)+24.9%+5.2%4th highest of 19
Operating margin18.5%8.9%6th highest of 19
EV / Sales6.7×2.5×4th most expensive of 18
Growth the price implies (Req g, 7 yrs)33.9%1.5%most demanding of 12
Growth delivered (Del g)+10.1%+0.5%5th highest of 12
Hurdle (Req g minus delivered)+23.8 pp-3.1 pp2nd most demanding of 12
ROIC minus cost of capital-0.5 pp+1.2 pp7th lowest of 17
EV / EBITDA30.4×9.7×most expensive of 7
Net debt / EBITDA-0.5×-0.5×4th least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%

Questions

Which companies are Bliss GVS Pharma's closest peers?
The cockpit's peer set: Sichuan Neautus Traditional Chinese (2206.HK), Zhejiang Int'l (000411.SZ), Guizhou Xinbang Pharmaceutical (002390.SZ), Ardelyx (ARDX), Jinghua Pharmaceutical (002349.SZ), Lexicon Pharmaceuticals (LXRX), Katakura Industries (3001.T), Bambusa Therapeutics (BBTX).
Is Bliss GVS Pharma expensive compared with its peers?
On ev / sales it trades at 6.7× against a peer median of 2.5×, 4th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Bliss GVS Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +140.6% against -7.0% for the median peer; over one year +323.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.